Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 10/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522134 | 1.00 | XDH (0.48) | XDHELANENLRP3TLR4RAB9A | |
| SCHEMBL5524517 | 0.86 | XDH (0.46) | XDHELANENLRP3TLR4RAB9A | |
| SCHEMBL4047646 | 0.86 | XDH (0.46) | XDHELANENLRP3TLR4RAB9A | |
| SCHEMBL3959052 | 0.83 | XDH (0.46) | XDHELANENLRP3TLR4RAB9A | |
| SCHEMBL3955590 | 0.83 | XDH (0.46) | XDHELANENLRP3TLR4RAB9A | |
| SCHEMBL4050549 | 0.82 | DAGLA (0.43) | XDHELANEDAGLA | |
| SCHEMBL5529494 | 0.82 | DAGLA (0.43) | XDHELANEDAGLA | |
| SCHEMBL4049876 | 0.81 | XDH (0.44) | XDHRAB9ANPC1KDM4EGLO1 | |
| SCHEMBL5524842 | 0.81 | XDH (0.44) | XDHRAB9ANPC1KDM4EGLO1 | |
| SCHEMBL11929986 | 0.81 | ELANE (0.50) | XDHELANEKDM4EFAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | claimed |
| JP-2007535568-A | — | — | 2007-12-06 | — | — | JP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | claimed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | XDH 2113/4885ELANE 104/4885NLRP3 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.